1st American Conference on Reconstructive Transplant Surgery

第一届美国重建移植手术会议

• 批准号: 7541669
• 负责人: Joseph Serletti
• 金额: $ 0.3万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-07 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7541669
• 关键词: Achievement; Address; Adverse effects; Aftercare; Allografting; Ally; American; Communication; Defect; Deformity; Dissection; Face; Faculty; Fostering; Funding; Future; Hand; Health Professional; Immunologist; Immunology; Immunosuppression; Immunosuppressive Agents; International; Knowledge; Operative Surgical Procedures; Organ Transplantation; Organ failure; Other Body Part; Paper; Participant; Physicians; Plastics; Psychiatrist; Purpose; Reconstructive Surgical Procedures; Solid; Therapeutic immunosuppression; Tissues; Transplant Surgeon; Transplantation; Upper arm; composite tissue transplantation; day; frontier; insight; medical specialties; member; novel; programs; reconstruction; symposium; tumor

DESCRIPTION (provided by applicant): This is an application for partial funding of the "First American Conference on Reconstructive Transplant Surgery (ACRTS): Exploring the new era of Composite Tissue Allotransplantation (CTA)", a two day meeting with didactic, panel and submitted paper sessions intended to provide plastic, reconstructive and transplant surgeons, immunologists, psychiatrists and other allied health professionals in these fields with: 1) Overview of the current status in hand and face transplantation 2) Understanding of appropriate immunosuppressive treatment in Composite Tissue Allotransplantation 3) Insight into strategies for induction of tolerance towards an allograft 4) Guidance on how to establish a hand or face transplant program 5) Knowledge of potential future applications of Reconstructive Transplant Surgery The invited course faculty members are international experts in this field with first hand knowledge in reconstructive transplant surgery and composite tissue allotransplantation. It is the purpose of this meeting to provide the participant with the very latest achievements in transplant immunology and with strategies that have been used successfully to minimize long-term immunosuppressive treatment after organ transplantation. As the side effects related to conventional immunosuppression currently represent the major limiting factor for wide spread use of Composite Tissue Allotransplantation, the successful implementation of such strategies in CTA would result in a major breakthrough in this field. As we anticipate this to be realized within the next years, a second focus of this conference is to discuss the large variety of indications for CTA. Questions to be addressed include but are not limited to: " CTA for reconstruction after tumor dissection " CTA for reconstruction in inborn deformities " Arm transplantation " CTA for reconstruction of defects in body part other than hand and face As a third objective, this conference provides an educational objective to physicians that are intending to launch a CTA program and aims for intensification of the communication and exchange between participating centers. After solid organ transplantation has become a routine treatment for organ failure, the next frontier in this field is the transplantation of "composite tissue" like the hand or the face in order to serve the unmet need for major tissue reconstruction. In this meeting, we bring together the leaders of both reconstructive surgery and transplant immunology in order to foster the interaction between these two specialties and to promote the implementation of the progress achieved in transplantation into Composite Tissue Allotransplantation in order to enable wide spread application of this novel treatment.

描述（由申请人提供）： 这是“第一届美国重建移植手术会议（ACRTS）的部分资金申请：探索复合组织同种异体移植（CTA）的新时代”，为期两天的会议，旨在为整形，重建和移植外科医生，免疫学家，精神病学家和这些领域的其他专职医疗人员提供教学，小组和提交论文会议：1）手和面部移植的现状概述2）了解复合组织同种异体移植中适当的免疫抑制治疗3）深入了解诱导同种异体移植耐受的策略4）指导如何建立手或面部移植程序5）重建移植手术的潜在未来应用的知识受邀课程教师是在重建移植手术和复合组织同种异体移植的第一手知识在这一领域的国际专家。本次会议的目的是为与会者提供移植免疫学的最新成果，以及已成功用于减少器官移植后长期免疫抑制治疗的策略。由于与常规免疫抑制相关的副作用目前代表了广泛使用复合组织同种异体移植的主要限制因素，因此在CTA中成功实施此类策略将导致该领域的重大突破。由于我们预计这将在未来几年内实现，本次会议的第二个重点是讨论CTA的各种适应症。需要解决的问题包括但不限于：“用于肿瘤切除后重建的CTA“用于先天性畸形重建的CTA“手臂移植“用于手和面部以外的身体部位缺陷重建的CTA作为第三个目标，本次会议为打算启动CTA计划的医生提供了一个教育目标，旨在加强沟通，参与中心之间的交流。在实体器官移植已成为器官衰竭的常规治疗方法后，该领域的下一个前沿是手或脸等“复合组织”的移植，以满足主要组织重建的未满足需求。在这次会议上，我们汇集了重建外科和移植免疫学的领导者，以促进这两个专业之间的互动，并促进移植到复合组织同种异体移植中所取得的进展的实施，以使这种新的治疗方法得到广泛的应用。